Skip to main content

Advertisement

SpringerLink
Log in

Treatment of nonalcoholic fatty liver disease

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Nonalcoholic fatty liver disease (NAFLD) is very common in the United States, and in some patients it may lead to cirrhosis, liver failure, and liver cancer. NAFLD encompasses a spectrum of liver injury, ranging from steatosis to steatohepatitis, advanced fibrosis, and cirrhosis. Nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD, histologically comprises steatosis, balloon degeneration, inflammation, and fibrosis in varying degrees. It is generally believed that simple steatosis is benign with minimal risk of progression, whereas NASH is progressive and can lead to cirrhosis. The commonly associated risk factors for NAFLD include obesity, hyperlipidemia, and diabetes mellitus. The pathogenesis of NAFLD and NASH is not fully known; however, current evidence suggests that insulin resistance and lipid peroxidation play a role in the pathogenesis of this condition. Currently, there are no proven effective therapies available for the treatment of NASH. Although there are numerous studies that have explored various treatments for NASH, these generally consist of small numbers of patients with suboptimal endpoints. Treatment strategies for NAFLD and NASH can be broadly divided into 1) treatment or control of underlying risk factors such as hyperlipidemia, diabetes mellitus, and obesity; and 2) specific pharmacologic therapy such as insulin sensitizers, antioxidants, or cytoprotective agents. Newer thiazolidinediones, such as rosiglitazone and pioglitazone, have shown promise in the treatment of NASH in pilot studies. However, these agents should not be used in clinical practice until their efficacy and safety are firmly established in larger studies. Despite encouraging initial studies, the recently completed multicenter, randomized, controlled trial failed to show any efficacy for ursodeoxycholic acid in the treatment of NASH. Other agents, such as vitamin E, betaine, probucol, and atorvastatin, have been explored as therapeutic agents for NASH. However, none of these studies have shown convincingly their utility in the treatment of NASH. Attempts to identify optimal therapy for patients with NASH are being vigorously pursued by the research community and important advances are expected within next several years. Until then, subjects should be advised to avoid alcohol, lose weight, and exercise regularly, and meticulous attention should be paid to the control of their risk factors such as diabetes and hyperlipidemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37:1202–1219. A comprehensive and well-summarized review of NASH based on the proceedings from a recent single-topic symposium sponsored by American Association for the Study of Liver Disease.

    Article  PubMed  Google Scholar 

  2. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649–1657.

    Article  PubMed  Google Scholar 

  3. Ballentani S, Saccoccio G, Masutti F, et al.: Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000, 132:112–117.

    Google Scholar 

  4. Araujo LM, DeOliveira A, Nunes DS: Liver and biliary sonography in diabetic and non-diabetic obese woman. Diabetes Metab 1998, 24:458–462.

    PubMed  CAS  Google Scholar 

  5. Hilden M, Christoffersen P, Juhle E, et al.: Liver histology in a ‘normal’ population-examination of 503 consecutive fatal traffic casualities. Scand J Gastroenterol 1977, 12:593–597.

    Article  PubMed  CAS  Google Scholar 

  6. McCullough AJ: Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002, 34:255–262.

    Article  PubMed  Google Scholar 

  7. Itoh S, Yougel T, Kawagoe K: Comparison between nonalcoholic steatohepatitis and alcoholic steatohepatitis. Am J Gastroenterol 1987, 82:650–654.

    PubMed  CAS  Google Scholar 

  8. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy with analysis of risk factors. Hepatology 1990, 12:1106–1110.

    Article  PubMed  CAS  Google Scholar 

  9. Silverman JF, O’Brien KF, Long S, et al.: Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990, 85:1349–1355.

    PubMed  CAS  Google Scholar 

  10. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221–1231.

    Article  PubMed  CAS  Google Scholar 

  11. American Gastroenterological Association Medical Position Statement: Nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1702–1704. Comprehensive and well-written summary and evidencebased position statement by the American Gastroenterological Association.

  12. Clark JM, Diehl AM: Nonalcoholic fatty liver disease. An unrecognized cause of cryptogenic cirrhosis. JAMA 2003, 289:300–304.

    Article  Google Scholar 

  13. Sanyal AJ, Campbell-Sargent C, Mirshani F, et al.: Nonalcoholic steatohepatitis association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183–1192.

    Article  PubMed  CAS  Google Scholar 

  14. Willner IR, Waters B, Patil SR, et al.: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001, 96:2957–2961.

    Article  PubMed  CAS  Google Scholar 

  15. Marchesini G, Brizi M, Marsell-Labate AM, et al.: Association of nonalcoholic liver disease with insulin resistance. Am J Med 1999, 107:450–455.

    Article  PubMed  CAS  Google Scholar 

  16. Chalasani N, Deeg MA, Persohn S, et al.: Metabolic and anthropometric evaluation of insulin resistance in non-diabetic patients with non-alcoholic steatohepatitis. Am J Gastroentertol 2003, in press.

  17. Esterbauer H, Schaur RJ, Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, maloaldehyde and related aldehydes. Free Radic Biol Med 1991, 11:81–128.

    Article  PubMed  CAS  Google Scholar 

  18. Niemela O, Parkkila S, Juvonen RO, et al.: Cytochrome P450 2A6, 2E1, and 3A4 and production of protein aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver disease. J Hepatol 2000, 33:893–901.

    Article  PubMed  CAS  Google Scholar 

  19. Chalasani N, Gorski JC, Asghar MS, et al.: Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003, 37:544–550.

    Article  PubMed  CAS  Google Scholar 

  20. Drenick EJ, Fisler J, Johnson D: Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982, 82:535–548.

    PubMed  CAS  Google Scholar 

  21. Koteish A, Diehl AM: Animal models of steatosis. Semin Liver Dis 2001, 21:89–104.

    Article  PubMed  CAS  Google Scholar 

  22. Tilg H, Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343:1467–1476.

    Article  PubMed  CAS  Google Scholar 

  23. Wigg AJ, Robert-Thompson IC, Dymock RB, et al.: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206–211.

    Article  PubMed  CAS  Google Scholar 

  24. Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705–1725.

    Article  PubMed  Google Scholar 

  25. Luyckx FH, Desaive C, Thiry A, et al.: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998, 22:222–226.

    Article  PubMed  CAS  Google Scholar 

  26. Ranlov I, Hardt F: Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990, 47:208–214.

    Article  PubMed  CAS  Google Scholar 

  27. Eriksson S, Eriksson KF, Bondesson L: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986, 220:83–88.

    Article  PubMed  CAS  Google Scholar 

  28. Luyckx FH, Lefebvre PJ, Scheen AJ: Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000, 26:98–106.

    PubMed  CAS  Google Scholar 

  29. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99:1408–1413.

    PubMed  CAS  Google Scholar 

  30. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158:1855–1867.

  31. Barlow SE, Dietz WH: Obesity evaluation and treatment: expert committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998, 102:E29.

    Article  PubMed  CAS  Google Scholar 

  32. Anderson T, Gluud C, Franzmann MB, et al.: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991, 12:224–229.

    Article  Google Scholar 

  33. Okita M, Hayashi M, Sasagawa T, et al.: Effect of a moderate energy-restricted diet on obese patients with fatty liver. Nutrition 2001, 17:542–547.

    Article  PubMed  CAS  Google Scholar 

  34. Ueno T, Sugawara H, Sujaku K, et al.: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27:103–107.

    Article  PubMed  CAS  Google Scholar 

  35. Assy N, Svalb S, Hussein O: Orlistat (Xenical) reverses fatty liver disease and improved hepatic fibrosis in obese patients with NASH. Hepatology 2001, 34(suppl):458A.

    Google Scholar 

  36. Harrison SA, Fincke C, Helinski D, et al.: Orlistat treatment in obese, non-alcoholic steatohepatitis patients: a pilot study. Hepatology 2002, 36:406A.

    Google Scholar 

  37. Harrison SA, Ramrakhiani S, Brunt EM, et al.: Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003, 98:926–930.

    Article  PubMed  CAS  Google Scholar 

  38. Laurin J, Lindor KD, Crippin JS, et al.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholicinduced steatohepatitis: a pilot study. Hepatology 1996, 23:1464–1467.

    Article  PubMed  CAS  Google Scholar 

  39. Basaranoglu M, Acbay O, Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999, 31:384.

    Article  PubMed  CAS  Google Scholar 

  40. Horlander JC, Kwo PY, Cummings OW: Atorvastatin for the treatment of NASH. Gastroenterology 2001, 120:A544.

    Article  Google Scholar 

  41. Marchesini G, Brizi M, Bianchi G, et al.: Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893–894.

    Article  PubMed  CAS  Google Scholar 

  42. Nair S, Diehl AM, Perillo R: Metformin in nonalcoholic steatohepatitis: efficacy and safety: a preliminary report. Gastroenterology 2002, 122:A621.

    Google Scholar 

  43. Neuschwander-Tetri BA, Brunt EM, Wehmeier, et al.: Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with nonalcoholic steatohepatitis. J Hepatol 2003, 38:434–440. Interim data on rosiglitazone in NASH patients. The study is now completed and final results are awaited.

    Article  PubMed  CAS  Google Scholar 

  44. Caldwell SH, Hespenheide EE, Redick JA, et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:519–525.

    Article  PubMed  CAS  Google Scholar 

  45. Azuma T, Tomita K, Kato S, et al.: A pilot study of thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis. Hepatology 2002, 36:406A.

    Google Scholar 

  46. Acosta RC, Molina EG, O’Brien CB, et al.: The use of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology 2001, 120:A546.

    Article  Google Scholar 

  47. Sanyal AJ, Contos AJ, Sargeant C, et al.: A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis. Hepatology 2002, 36:A382.

    Google Scholar 

  48. Promrat K, Luchman G, Kleiner DE, et al.: Pilot study of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology 2003, 124:A708.

    Article  Google Scholar 

  49. Lavine JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136:734–738. This is the only study to date looking at a cytoprotective agent, vitamin E, in pediatric patients with NASH.

    Article  PubMed  CAS  Google Scholar 

  50. Hasegawa T, Yoneda M, Nakamura K, et al.: Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001, 15:1667–1672.

    Article  PubMed  CAS  Google Scholar 

  51. Kugelmas M, Hill DB, Vivian B, et al.: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38:413–419.

    Article  PubMed  CAS  Google Scholar 

  52. Kowdley KV: Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000, 108:481–486.

    Article  PubMed  CAS  Google Scholar 

  53. Guma G, Viola L, Thome M, et al.: Ursodeoxycholic acid in the treatment on nonalcoholic steatohepatitis: results of a prospective clinical trial. Hepatology 1997, 26:A387.

    Article  Google Scholar 

  54. Ceriani R, Brunati S, Morini L, et al.: Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis. Hepatology 1998, 28:A386.

    Google Scholar 

  55. Lindor KD (UDCA/NASH study group): Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized, placebo-controlled trial. Gastroenterology 2003, 124:A708.

    Article  Google Scholar 

  56. Merat S, Malekzadeh R, Sohrabi MR, et al.: Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003, 38:414–418.

    Article  PubMed  CAS  Google Scholar 

  57. Barak AJ, Beckenhauer HC, Junnila M, et al.: Dietary betaine promotes generation of hepatitis S-adenosylmethionine and protects the liver from ethanolinduced fatty infiltration. Alcohol Clin Exp Res 1993, 17:552–555.

    Article  PubMed  CAS  Google Scholar 

  58. Abdelmalek MF, Angulo P, Jorgensen RA, et al.: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96:2711–2717.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Gastroenterology/Hepatology and Clinical Pharmacology, Indiana University School of Medicine, 1001 West 10th Street, WD OPW 2005, 46202, Indianapolis, IN, USA

    Suthat Liangpunsakul MD & Naga Chalasani MD

Authors
  1. Suthat Liangpunsakul MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naga Chalasani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liangpunsakul, S., Chalasani, N. Treatment of nonalcoholic fatty liver disease. Curr Treat Options Gastro 6, 455–463 (2003). https://doi.org/10.1007/s11938-003-0047-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-003-0047-0

Keywords

Search

Navigation